 |
VasoMedical to Showcase EECP® Therapy at Expomed 2013 in Istanbul, Turkey |
WESTBURY, N.Y. March 22, 2013 – VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, announced today that that the Company will attend and exhibit at Expomed 2013, April 4-7, 2013 in Istanbul, Turkey.
Expomed is an international healthcare exhibition showcasing medical analysis, diagnosis, treatment, rehabilitation product, device, system, technology, equipment and hospitals. Approximately 1,200 companies and company representatives will exhibit some of the latest developments, technologies and insights across the entire healthcare sector. At this event, VasoMedical will present its core technology, EECP® Therapy, its BIOX line of ambulatory monitoring systems and software, as well as additional patient management products.
“Expomed is an important Eurasian platform to allow healthcare professionals across the globe to discover new technologies and developments in the medical field,” said Larry Liebman, vice president, sales & marketing for VasoMedical. “This environment provides VasoMedical with the opportunity to continue to spread awareness about the Company's offerings, particularly its EECP® Therapy, a safe and effective non-invasive treatment for patients suffering from heart diseases such as angina and heart failure.”
Mr. Liebman continued, “By showcasing EECP® at Expomed, one of our main goals is to continue to generate buzz about the positive benefits of EECP® Therapy in Turkey and the Eurasian region. We'd like more physicians to start turning to this Therapy as a treatment option for their patients, and the first step to achieving that goal is to educate them on the benefits of the Therapy. EECP® Therapy has already enhanced the lives of many patients in Turkey and around the world, and it continues to prove to be an effective option for those who are suffering from various heart conditions.”
“Additionally, the growing healthcare markets in the Eurasian region are looking for products like our BIOX ECG Holter and ambulatory blood pressure monitors, products with rich features and at reasonable prices that can meet the diagnostic needs of clinicians,” Mr. Liebman noted.
VasoMedical will be located at Booth 1207 in the Tüyap Fair Convention and Congress Center.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
About BIOX
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, BIOX continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at www.biox.com.cn.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com